Stocks of Exact Sciences Corp (NASDAQ:EXAS) traded higher last session on Wall Street, down -2.33% to $56.28.
EXAS stock price is now 15.59% away from the 50-day moving average and 0.17% away from the 200-day moving average. The market capitalization of the company currently stands at $10.62B.
With the price target of $60, Mizuho recently initiated with Outperform rating for Exact Sciences Corp (NASDAQ: EXAS). On March 13, 2025, RBC Capital Mkts recently initiated its ‘Sector Perform’ rating on the stock quoting a target price of $52, while ‘Barclays’ rates the stock as ‘Overweight’
In other news, Conroy Kevin T, President and CEO bought 19,500 shares of the company’s stock on Nov 13 ’24. The stock was bought for $1,001,325 at an average price of $51.35. Upon completion of the transaction, the President and CEO now directly owns 1,074,191 shares in the company, valued at $60.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 08 ’24, EVP, GM, Precision Oncology Baranick Brian sold 929 shares of the business’s stock. A total of $65,030 was realized by selling the stock at an average price of $70.00. This leaves the insider owning 12,758 shares of the company worth $0.72 million. A total of 1.47% of the company’s stock is owned by insiders.
During the past 12 months, Exact Sciences Corp has had a low of $39.97 and a high of $72.83. As of last week, the company has a debt-to-equity ratio of 1.06, a current ratio of 2.73, and a quick ratio of 2.38.
The net profit margin was -36.06% and return on equity was -36.89% for EXAS. The company reported revenue of $706.78 million for the quarter, compared to $637.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.86 percent.
